Dupixent (dupilumab) is one of the most widely prescribed biologic medications in the United States. Doctors use it to treat ...

A painless brush swab may soon change one of the most unpleasant parts of oral cancer care, sorting dangerous mouth lesions ...

Dispatch Bio is building a system that could broaden treatment for a wide variety of tumors, and it’s about to start testing ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future growthHighlights validation of T-cell engager modality with mRNA-2808 in multiple myelo ...

The global stem cell banking market is experiencing robust compound annual growth rate (CAGR) expansion, driven by escalating demand-side dynamics, rising awareness of regenerative medicine ...

The renal cancer pipeline presents key opportunities in developing novel therapies targeting immunosuppression and oncogenic pathways. Notable advancements include combinations like Quavonlimab with ...

The SUBITO trial, presented by Rianne L Seefat and colleagues in The Lancet Oncology,1 revisits the long-standing debate ...

Eating a range of foods with high antioxidant content may be a big factor in living a longer life, according to research. Here are some of the flavonoid-rich staples to consider adding to your diet.

Researchers, entrepreneurs, investors and global pharmaceutical leaders gathered in Cambridge this week as the Milner ...

The Myelofibrosis market presents significant opportunities with over 50 companies developing 55+ pipeline drugs, focusing on novel therapeutic approaches. Key emerging drugs are Ropeginterferon ...

A quiet layer of biology is beginning to change how health is understood, and it sits on the surface of nearly every cell in your body. Scientists now say these tiny sugar structures, once ignored, ...

Natera delivers robust revenue growth, raising 2026 guidance to $2.74–$2.82 billion, but remains unprofitable. Read more on ...